Ibrance (palbociclib) for the Treatment of Metastatic Breast Cancer
Ibrance (palbociclib) is an oral formulation developed by Pfizer for the treatment of metastatic breast cancer in women with disease progression post endocrine therapy.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Oral Cancer | Pfizer | Pharmaceuticals | Women